May 27 2022


Nizatidine reaches a low concentration in milk, therefore it is not likely to develop adverse effects in infants. It is estimated, from a rather limited number of observations, that an infant can reach take less than 1% of the maternal dose.

Although anti-H 2 may increase prolactin, there are no published cases of lactating women affected by this drug.

Warning of the manufacturer:

Studies conducted in lactating women have shown that nizatidine is excreted in milk (0.1% of the dose given to the mother), in a proportional relationship to the maternal plasma concentration. Due to growth retardation in the offspring of rats treated with nizatidine, this drug should only be administered if considered absolutely necessary.